The	DT
Role	NN
of	IN
PPARs	NNS
in	IN
Lung	NN
Fibrosis	NN
.	.

Pulmonary	JJ
fibrosis	NN
is	VBZ
a	DT
group	NN
of	IN
disorders	NNS
characterized	VBN
by	IN
accumulation	NN
of	IN
scar	NN
tissue	NN
in	IN
the	DT
lung	NN
interstitium	NN
,	,
resulting	VBG
in	IN
loss	NN
of	IN
alveolar	JJ
function	NN
,	,
destruction	NN
of	IN
normal	JJ
lung	NN
architecture	NN
,	,
and	CC
respiratory	JJ
distress	NN
.	.

Some	DT
types	NNS
of	IN
fibrosis	NN
respond	VBP
to	TO
corticosteroids	NNS
,	,
but	CC
for	IN
many	JJ
there	EX
are	VBP
no	DT
effective	JJ
treatments	NNS
.	.

Prognosis	NN
varies	VBZ
but	CC
can	MD
be	VB
poor	JJ
.	.

For	IN
example	NN
,	,
patients	NNS
with	IN
idiopathic	JJ
pulmonary	JJ
fibrosis	NN
(	(
IPF	NN
)	)
have	VBP
a	DT
median	JJ
survival	NN
of	IN
only	RB
2.9	CD
years	NNS
.	.

Prognosis	NN
may	MD
be	VB
better	RBR
in	IN
patients	NNS
with	IN
some	DT
other	JJ
types	NNS
of	IN
pulmonary	JJ
fibrosis	NN
,	,
and	CC
there	EX
is	VBZ
variability	NN
in	IN
survival	NN
even	RB
among	IN
individuals	NNS
with	IN
biopsy-proven	JJ
IPF	NN
.	.

Evidence	NN
is	VBZ
accumulating	VBG
that	IN
the	DT
peroxisome	NN
proliferator-activated	JJ
receptors	NNS
(	(
PPARs	NNS
)	)
play	VBP
important	JJ
roles	NNS
in	IN
regulating	VBG
processes	NNS
related	VBN
to	TO
fibrogenesis	NN
,	,
including	VBG
cellular	JJ
differentiation	NN
,	,
inflammation	NN
,	,
and	CC
wound	NN
healing	NN
.	.

PPARalpha	NN
agonists	NNS
,	,
including	VBG
the	DT
hypolidipemic	JJ
fibrate	NN
drugs	NNS
,	,
inhibit	VBP
the	DT
production	NN
of	IN
collagen	NN
by	IN
hepatic	JJ
stellate	NN
cells	NNS
and	CC
inhibit	VBP
liver	NN
,	,
kidney	NN
,	,
and	CC
cardiac	JJ
fibrosis	NN
in	IN
animal	NN
models	NNS
.	.

In	IN
the	DT
mouse	NN
model	NN
of	IN
lung	NN
fibrosis	NN
induced	VBN
by	IN
bleomycin	NN
,	,
a	DT
PPARalpha	NN
agonist	NN
significantly	RB
inhibited	VBD
the	DT
fibrotic	JJ
response	NN
,	,
while	IN
PPARalpha	NN
knockout	NN
mice	NNS
developed	VBD
more	RBR
serious	JJ
fibrosis	NN
.	.

PPARbeta/delta	NN
appears	VBZ
to	TO
play	VB
a	DT
critical	JJ
role	NN
in	IN
regulating	VBG
the	DT
transition	NN
from	IN
inflammation	NN
to	TO
wound	VB
healing	NN
.	.

PPARbeta/delta	NN
agonists	NNS
inhibit	VBP
lung	NN
fibroblast	NN
proliferation	NN
and	CC
enhance	VBP
the	DT
antifibrotic	JJ
properties	NNS
of	IN
PPARgamma	NN
agonists	NNS
.	.

PPARgamma	NN
ligands	NNS
oppose	VBP
the	DT
profibrotic	JJ
effect	NN
of	IN
TGF-beta	NN
,	,
which	WDT
induces	VBZ
differentiation	NN
of	IN
fibroblasts	NNS
to	TO
myofibroblasts	NNS
,	,
a	DT
critical	JJ
effector	NN
cell	NN
in	IN
fibrosis	NN
.	.

PPARgamma	NN
ligands	NNS
,	,
including	VBG
the	DT
thiazolidinedione	JJ
class	NN
of	IN
antidiabetic	JJ
drugs	NNS
,	,
effectively	RB
inhibit	VBP
lung	NN
fibrosis	NN
in	FW
vitro	FW
and	CC
in	IN
animal	NN
models	NNS
.	.

The	DT
clinical	JJ
availability	NN
of	IN
potent	JJ
and	CC
selective	JJ
PPARalpha	NN
and	CC
PPARgamma	NN
agonists	NNS
should	MD
facilitate	VB
rapid	JJ
development	NN
of	IN
successful	JJ
treatment	NN
strategies	NNS
based	VBN
on	IN
current	JJ
and	CC
ongoing	JJ
research	NN
.	.

